Cystatin C: What This Test Actually Measures

What Cystatin C Is and Why It Matters

Cystatin C is a 13-kilodalton protein belonging to the cystatin superfamily of cysteine protease inhibitors. Every nucleated cell in the body produces it at a near-constant rate, which is the single feature that makes it useful as a kidney biomarker [1]. The kidneys filter cystatin C freely at the glomerulus, then the proximal tubule reabsorbs and catabolizes it almost completely. None of it returns to the bloodstream.

A Steady-State Production Model

Because cystatin C production does not depend on muscle mass, dietary protein intake, or sex hormone levels, its serum concentration tracks GFR more directly than creatinine does [2]. Creatinine is a breakdown product of skeletal muscle creatine. A 90-kg male weightlifter and a 50-kg sedentary woman can have identical kidney function yet wildly different serum creatinine values. Cystatin C sidesteps that problem.

Clinical Adoption Timeline

The protein was first identified in cerebrospinal fluid in 1961, but its role as a filtration marker did not gain traction until the early 2000s. The 2012 KDIGO Clinical Practice Guideline for Evaluation and Management of CKD formally recommended cystatin C as a confirmatory biomarker when creatinine-based eGFR results are imprecise or misleading [3]. That recommendation was reinforced in the 2021 CKD-EPI equation update, which removed the race coefficient from creatinine-based eGFR and offered a combined creatinine-cystatin C equation as the preferred alternative [4].

How the Test Works

A cystatin C test requires a simple venous blood draw. No fasting is necessary, and the sample can be collected at any time of day. Labs measure serum cystatin C concentration using particle-enhanced nephelometric or turbidimetric immunoassays, both of which have been standardized against the international reference material ERM-DA471/IFCC [5].

From Concentration to eGFR

The raw cystatin C value (mg/L) is plugged into a validated equation to estimate GFR. The 2021 CKD-EPI cystatin C equation yields eGFRcys, and the combined 2021 CKD-EPI creatinine-cystatin C equation yields eGFRcr-cys. A meta-analysis published in the New England Journal of Medicine (N = 5,352 participants across 13 studies) found that eGFRcr-cys was more accurate than either marker alone, correctly classifying CKD stage in 91.5% of cases compared with 87.2% for creatinine-only eGFR [6].

When Results Come Back

Most commercial labs report cystatin C within one to three business days. Quest Diagnostics and Labcorp both offer the assay on standard renal panels when ordered. Point-of-care cystatin C testing is not yet widely available in outpatient clinics, though research prototypes exist.

Normal Cystatin C Range

The generally accepted adult reference interval is 0.55 to 1.15 mg/L, though slight variation occurs between assay platforms [7]. Mayo Clinic Laboratories lists 0.53 to 0.95 mg/L for adults aged 18 to 49, with the upper limit rising modestly with age. Cleveland Clinic uses 0.56 to 0.98 mg/L for its nephelometric assay.

Age and Pediatric Considerations

Neonates have higher cystatin C levels (up to 1.7 mg/L) that decline rapidly during the first year of life, reaching adult-range values by approximately 12 months [8]. In older adults, cystatin C levels rise gradually because GFR declines with aging, not because production increases. This age-related increase actually reflects true kidney function loss, unlike creatinine, which may remain falsely "normal" in elderly patients who have lost muscle mass.

Why a "Normal" Number Can Still Signal Risk

A 2012 study in JAMA (N = 11,909 community-dwelling adults) demonstrated that cystatin C levels in the highest quartile of the "normal" range (0.95 to 1.05 mg/L) were associated with a 50% higher risk of cardiovascular events compared with the lowest quartile, even after adjusting for traditional risk factors [9]. The 2012 KDIGO guideline committee noted that "cystatin C may identify a preclinical stage of kidney impairment not detected by creatinine" [3].

Cystatin C vs. Creatinine: Key Differences

Creatinine has been the default kidney biomarker for decades. It is inexpensive, universally available, and well understood. But it has blind spots that cystatin C fills.

Muscle Mass Bias

Creatinine production is proportional to skeletal muscle mass. In patients with sarcopenia, limb amputation, or chronic illness causing muscle wasting, serum creatinine underestimates kidney damage by staying deceptively low [10]. Cystatin C is unaffected by these conditions. A prospective cohort study in the Journal of the American Society of Nephrology (N = 3,030 elderly adults) showed that 9.4% of participants classified as having normal kidney function by creatinine-based eGFR were reclassified to CKD stage 3a when cystatin C was added [11].

The Race Coefficient Problem

Before 2021, creatinine-based eGFR equations (CKD-EPI 2009 and MDRD) included a race-adjustment coefficient that assigned higher eGFR values to Black patients. A task force convened by the National Kidney Foundation and the American Society of Nephrology recommended removing that coefficient and instead using the combined creatinine-cystatin C equation to improve accuracy across all populations [4]. The NKF-ASN task force stated: "The use of cystatin C, either alone or combined with creatinine, offers a race-free approach to estimating GFR" [4].

Cost and Availability

Creatinine testing costs $3 to $10. Cystatin C costs $30 to $80 and is not included on basic metabolic panels. That price gap explains why creatinine remains the first-line screening test in most clinical settings, with cystatin C reserved for confirmatory or high-risk situations.

When Clinicians Order Cystatin C

Not every patient needs a cystatin C test. Guidelines from KDIGO and the NKF-ASN task force identify specific clinical scenarios where cystatin C adds the most value [3][4].

Confirming Borderline CKD Staging

The most common indication is a creatinine-based eGFR between 45 and 59 mL/min/1.73 m², which places a patient at the threshold of CKD stage 3a. Adding cystatin C can push the combined eGFR above or below that cutoff, changing clinical management. A study in Annals of Internal Medicine (N = 4,637) found that 32% of patients initially staged as CKD 3a by creatinine alone were reclassified to a less severe category when cystatin C was incorporated [12].

Populations Where Creatinine Is Unreliable

Cystatin C is particularly useful in patients with extremes of muscle mass: bodybuilders whose high creatinine might falsely suggest kidney disease, or frail elderly patients whose low creatinine might mask it. It is also valuable in liver cirrhosis, where reduced hepatic creatine synthesis leads to artificially low creatinine, and in patients on trimethoprim or cimetidine, drugs that inhibit tubular creatinine secretion and falsely raise serum creatinine [10].

Cardiovascular Risk Stratification

Beyond nephrology, cystatin C has emerged as an independent predictor of cardiovascular outcomes. The Cardiovascular Health Study (N = 4,663 adults aged 65+) found that elevated cystatin C predicted heart failure, stroke, and all-cause mortality even after adjusting for creatinine-based eGFR and traditional cardiovascular risk factors [13].

What a High Cystatin C Level Means

A serum cystatin C above 1.15 mg/L generally indicates reduced GFR. The higher the value, the more impaired kidney filtration is.

Grading Severity

Using the CKD-EPI 2021 cystatin C equation, a cystatin C of 1.2 mg/L corresponds to an eGFRcys of roughly 68 mL/min/1.73 m² (mildly decreased). A cystatin C of 2.0 mg/L corresponds to an eGFRcys near 33 mL/min/1.73 m² (moderately to severely decreased). Values above 3.0 mg/L typically indicate stage 4 or 5 CKD [3].

Non-Kidney Causes of Elevation

A handful of conditions can raise cystatin C independently of GFR. Uncontrolled hyperthyroidism increases cystatin C production, potentially causing a 10 to 20% rise in serum levels [14]. High-dose glucocorticoid therapy (prednisone >20 mg/day) has also been associated with modest cystatin C elevation. Clinicians should account for these confounders before attributing a high result solely to kidney disease.

Next Steps After a High Result

A single elevated cystatin C should be confirmed with a repeat test and, when feasible, a paired creatinine measurement to calculate eGFRcr-cys. If the combined eGFR confirms CKD, the KDIGO 2024 guideline recommends checking urine albumin-to-creatinine ratio, electrolytes, and blood pressure to guide management [3].

What a Low Cystatin C Level Means

Low cystatin C (<0.55 mg/L) is uncommon and usually benign. It may reflect hyperfiltration, a state in which GFR is abnormally elevated.

Hyperfiltration in Early Diabetes

In early type 2 diabetes, the kidneys can hyperfiltrate at rates exceeding 130 mL/min/1.73 m², producing a paradoxically low cystatin C [15]. This is not reassuring. Hyperfiltration often precedes the development of diabetic kidney disease. The ADA Standards of Care (2024) recommend monitoring urine albumin annually in patients with diabetes regardless of eGFR [16].

Hypothyroidism and Low Cystatin C

Untreated hypothyroidism can suppress cystatin C production, yielding lower-than-expected values. Thyroid function should be checked if a low cystatin C result is discordant with clinical suspicion of reduced kidney function [14].

How to Lower Cystatin C

Because cystatin C reflects GFR, lowering it means improving kidney function or removing factors that artificially raise it. There is no drug that specifically reduces cystatin C production.

Blood Pressure Control

Hypertension is the second leading cause of CKD. The SPRINT trial (N = 9,361) demonstrated that targeting systolic blood pressure <120 mmHg reduced the composite renal outcome by 15% compared with the standard target of <140 mmHg [17]. ACE inhibitors and ARBs remain first-line agents for hypertensive CKD patients, as they reduce intraglomerular pressure and slow GFR decline [3].

Glycemic Management in Diabetes

In patients with diabetic kidney disease, SGLT2 inhibitors have shown kidney-protective effects independent of glucose lowering. The DAPA-CKD trial (N = 4,304) found that dapagliflozin reduced the risk of sustained eGFR decline by 39% compared with placebo over a median of 2.4 years [18]. While these trials used creatinine-based eGFR as the primary endpoint, the mechanism of action (reducing hyperfiltration) would be expected to normalize cystatin C as well.

Weight Management and GLP-1 Receptor Agonists

Obesity-related glomerulopathy is an increasingly recognized cause of elevated cystatin C. The FLOW trial (N = 3,533) showed that semaglutide 1.0 mg weekly reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and CKD [19]. Weight loss through any evidence-based method, including GLP-1 receptor agonists, dietary modification, or bariatric surgery, may improve GFR and reduce cystatin C in overweight patients with early kidney disease.

Lifestyle Factors

Smoking cessation, sodium restriction to <2,300 mg/day, and regular moderate exercise have all been associated with slower CKD progression in observational studies [3]. None of these interventions target cystatin C directly, but they protect kidney function.

How to Raise Cystatin C

Raising cystatin C is rarely a clinical goal. A low value typically reflects preserved or elevated GFR. If a clinician suspects the result is falsely low, the appropriate step is to identify and treat the underlying cause.

Treating Hypothyroidism

If hypothyroidism is suppressing cystatin C production, levothyroxine replacement to a goal TSH of 0.5 to 4.0 mIU/L will normalize production rates. Repeat cystatin C testing 6 to 8 weeks after achieving euthyroid status provides a more accurate GFR estimate [14].

Addressing Hyperfiltration

In early diabetic hyperfiltration, SGLT2 inhibitors reduce GFR toward normal by restoring tubuloglomerular feedback. This may paradoxically "raise" cystatin C into the normal range by correcting previously supranormal filtration [18]. The short-term eGFR dip seen in the first 2 to 4 weeks of SGLT2 inhibitor therapy is expected and not a reason to discontinue.

Limitations of Cystatin C Testing

No biomarker is perfect. Cystatin C has its own blind spots.

Thyroid and Steroid Interference

As noted above, hyperthyroidism raises cystatin C and hypothyroidism lowers it, independent of kidney function. Large doses of corticosteroids can also confound results. A 2015 meta-analysis in Clinical Chemistry (23 studies, N = 13,042) concluded that thyroid status was the most clinically significant non-GFR determinant of cystatin C [14].

Obesity

Some data suggest that adipose tissue produces small amounts of cystatin C, potentially causing slight overestimation of impairment in patients with BMI >35 [20]. The effect size is modest (approximately 5 to 8% elevation), but it is worth noting when interpreting borderline results in patients with severe obesity.

Standardization Gaps

While the IFCC reference material (ERM-DA471) has improved assay harmonization, inter-laboratory variation of 5 to 10% still exists, particularly between nephelometric and turbidimetric platforms [5]. Clinicians should use the same lab for serial monitoring.

The Role of Cystatin C in Medication Dosing

Many drugs are renally cleared and require dose adjustment when GFR drops. A more accurate GFR estimate means safer prescribing.

Practical Dosing Impact

For drugs with narrow therapeutic windows (vancomycin, lithium, methotrexate, direct oral anticoagulants), the difference between a creatinine-based eGFR of 55 and a cystatin C-confirmed eGFR of 42 can change the recommended dose by 25 to 50% [3]. This is not a theoretical concern. A retrospective analysis at a single academic medical center found that 14% of patients receiving renally dosed medications had discordant creatinine vs. Cystatin C eGFR values, and 6% were receiving inappropriate doses based on creatinine alone [21].

When to Request Cystatin C Before Prescribing

Consider ordering cystatin C before initiating nephrotoxic or renally cleared drugs in patients who are elderly (age >70), have low muscle mass, have liver disease, or have a creatinine-based eGFR between 30 and 60 mL/min/1.73 m². The 5 to 10 minutes spent waiting for the result can prevent a drug toxicity event.